Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Antimicrob Agents Chemother ; 60(10): 6365-8, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27458228

RESUMO

Teicoplanin is a key drug for the treatment of multiresistant staphylococcal bone and joint infections (BJI), yet can only be administered via a parenteral route. The objective of this study was to evaluate the safety and tolerability of subcutaneous (s.c.) teicoplanin for that indication over 42 days. Thirty patients with Gram-positive cocci BJI were included. Once the target of 25 to 40 mg/liter trough serum concentration was achieved, treatment was switched from an intravenous to an s.c. route. No discontinuation of teicoplanin related to injection site reaction and no severe local adverse event were observed. On multivariate analysis, better tolerability was observed at the beginning of treatment, in patients over 70 years old, and for dosages less than 600 mg. In conclusion, we recommend s.c. administration of teicoplanin when needed.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/sangue , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Teicoplanina/administração & dosagem , Teicoplanina/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Doenças Ósseas Infecciosas/tratamento farmacológico , Doenças Ósseas Infecciosas/microbiologia , Monitoramento de Medicamentos , Feminino , Cocos Gram-Positivos/patogenicidade , Humanos , Injeções Subcutâneas , Artropatias/tratamento farmacológico , Artropatias/microbiologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Teicoplanina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA